Merck KGaA announces its largest investment in Asia
May 31, 2024
Source: drugdu
88
Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea.
The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies.
Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies.
The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
